Earlier this week, the Food and Drug Administration approved Enstilar as a new topical therapy for plaque psoriasis in adults.
Enstilar is an aerosol foam that’s a combination of two medications: calcipotriene, a vitamin D-based treatment, and betamethasone dipropionate, a corticosteroid.
A Phase III clinical trial found that more than half of the patients using the foam had clear or almost clear skin after one month of use and achieved at least 75 percent improvement in their psoriasis severity, according to a statement released by LEO Pharma, Inc., the makers of Enstilar.
According to LEO, it is meant to be used once a day for up to four weeks, and can be applied across large areas of psoriasis on the body. It is expected to be available in pharmacies in January 2016. An ointment with this combination of medications, Taclonex, also by LEO, is already on the market.
For more information, visit Enstilar.com.
Driving discovery, creating community
For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.